225Ac-based radiopharmaceutical therapy has recently attracted great interest in prostate cancer, particularly 225Ac-PSMA-617 in small trials, demonstrating great efficacy, especially in the context of resistance to 177Lu-PSMA-617 (16,17). Here, FOLH1 is linked to prostate carcinoma.